Prevalence, Correlates, and Prognostic Relevance of Coronary Microvascular Dysfunction in Patients with Heart Failure and/or Cardiomyopathy (the PRECISION study)

Prevalence, Correlates, and Prognostic Relevance of Coronary Microvascular Dysfunction in Patients with Heart Failure and/or Cardiomyopathy (the PRECISION study) - Prevalence, Correlates, and Prognostic Relevance of Coronary Microvascular Dysfunction in Patients with Heart Failure and/or Cardiomyopathy (the PRECISION study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053793

Enrollment

200

Registered

2024-03-09

Start date

2024-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Cardiomyopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with heart failure or cardiomyopathy undergoing coronary angiography and CMD assessment with pressure wire.

Exclusion criteria

Exclusion criteria: Acute coronary syndrome Acute decompensated heart failure Visual stenosis of 90% or more in the left anterior descending artery on coronary angiography Renal dysfunction (GFR<30mL/min/1.73m2) not on dialysis Allergy against contrast agents Coronary artery bypass graft surgery

Design outcomes

Primary

Measure	Time frame
Frequency of coronary microvascular dysfunction	—

Secondary

Measure	Time frame
(1) Relationship between coronary microvascular dysfunction and the following factors: Patient characteristics Laboratory tests Biomarkers UCG findings Global ECV by cardiac CT (2) Clinical outcomes at 1, 2, 3, 4, 5 years Major adverse cardiovascular events, a composite of cardiovascular death and heart failure admission All-cause death Cardiovascular death Non-cardiovascular death Heart failure admission Cerebrovascular events Myocardial infarction Unplanned coronary revascularization Subgroup analysis HFpEF,HFrEF Cardiomyopathy (amyloidosis, hypertrophic cariomyopathy, dilated cariomyopathy, hypertensive heart disease, drug-induced cariomyopathy, sarcoidosis, tachycardia-induced cariomyopathy, etc)	—

Measure

Time frame

(1) Relationship between coronary microvascular dysfunction and the following factors: Patient characteristics Laboratory tests Biomarkers UCG findings Global ECV by cardiac CT (2) Clinical outcomes at 1, 2, 3, 4, 5 years Major adverse cardiovascular events, a composite of cardiovascular death and heart failure admission All-cause death Cardiovascular death Non-cardiovascular death Heart failure admission Cerebrovascular events Myocardial infarction Unplanned coronary revascularization Subgroup analysis HFpEF,HFrEF Cardiomyopathy (amyloidosis, hypertrophic cariomyopathy, dilated cariomyopathy, hypertensive heart disease, drug-induced cariomyopathy, sarcoidosis, tachycardia-induced cariomyopathy, etc)

—

Countries

Japan

Contacts

Public ContactDaisuke Sunohara

Shinshu University Hospital Department of Cardiovascular Medicine

sunoharadaisuke@shinshu-u.ac.jp0263373486

Outcome results